Vascular Access DeviceCIANO-ETINCT05299060
Effectiveness of Cyanoacrylate Glue in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients: Randomised Clinical Trial (CIANO-ETI)
A study testing cyanoacrylate adhesive (SecurePortIV®) and standard cure in people with Vascular Access Device and Catheterization, Peripheral, run by Hospital Arnau de Vilanova at 1 site in Spain.
Trial summary
Introduction: Venous access is increasingly necessary and essential in healthcare institutions, where more than 75% of hospitalised patients have some type of vascular access device cannulated. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Vascular Access Device, Catheterization, Peripheral, Nursing Care
- What is being tested?
- cyanoacrylate adhesive (SecurePortIV®) and standard cure
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 216 participants
- Where
- 1 siteSpain
- Study dates
- 16 Sep 2020to 30 Sep 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- over 18 years of age
- requiring cannulation of a midline catheter (BD-18580 PowerMidline™ 4F) or a PICC (BD-20178 PowerPICC™ 4.5 or 6 F)
- who accepted and signed the informed consent voluntarily
- with an inpatient unit admission of minimum 7 days
Who cannot join
- patients with skin conditions contraindicating the application of a skin glue or known allergy to cyanoacrylate, as recorded in the clinical history
Trial locations and contacts
1 site in 1 country.
About this study
Introduction: Venous access is increasingly necessary and essential in healthcare institutions, where more than 75% of hospitalised patients have some type of vascular access device cannulated. Due to their pathophysiological characteristics and pharmacological needs, some patients require special catheters, such as midline or peripherally inserted central catheters. In an attempt to reduce the main complications related to these, the safety of cyanoacrylate tissue adhesive has recently been demonstrated in the post-insertion treatment of vascular access devices.
Objective: To evaluate the efficacy of the use of cyanoacrylate tissue adhesive as fixation in the post-insertion of cannulated middle and central venous catheters with modified micro-Seldinger technique in acute hospitalized patients.
Read more
Methods: Randomised clinical trial with two groups(1:1): control and intervention. The control group received a cure with sutureless device plus transparent membrane and the intervention group received the same cure plus the cyanoacrylate glue. The study was approved by the Drug Research Ethics Committee of the Lleida health region. health region.
KEYWORDS: Cyanoacrylates; Vascular Access Device; Catheterization, Peripheral; Nursing Care; Randomized Controlled Trial.
Read the detailed description
A randomized clinical study with two arms (control group and intervention group) was performed.
Patients were selected according to whether they met the inclusion/exclusion criteria and all patients who met the criteria were offered to participate on a voluntary basis. These were collected by the intravenous therapy team (ETI) of the Arnau de Vilanova University Hospital (HUAV) in Lleida, from September 16, 2020 until the completion of the collection of the total number of patients required for the study (n=216).
Patients required insertion of a midline venous catheter (BD-18580 PowerMidline™ 4F) or a peripherally inserted central catheter (BD-20178 PowerPICC™ 4,5 or 6 F), according to the ETI-HUAV algorithm. All insertions were performed with the aid of ultrasound as a guiding technique. In addition, all patients underwent dermatotomy during the technique and the application of a post-insertion hemostasis protocol for at least 2 minutes or until the insertion site stopped bleeding, in order to unify the researchers' criteria.
After insertion of the vascular access device, the control group underwent the standard dressing: transparent polyurethane dressing with reinforced edge (3M®-1655 Tegaderm™ IV) and Sutureless Fixation Device (BD-19940 StatLock™ PICC Plus); and the intervention group, the standard dressing plus application of cyanoacrylate tissue adhesive (SP-015V SecurePortIV™ from Adhezion Biomedical, Llc.).
Afterwards, 3 scheduled cures were performed, at 24 hours, 72 hours and 7 days post-insertion, looking for the main complications: bleeding and/or pericatheter exudate, catheter displacement, signs of phlebitis and catheter-related pain.
- Conditions
- Vascular Access Device, Catheterization, Peripheral, Nursing Care, Randomized Controlled Trial
- Being tested
- cyanoacrylate adhesive (SecurePortIV®), standard cure
- Keywords
- Cyanoacrylates, Cyanoacrylate, Tissue adhesive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cyanoacrylate adhesive (SecurePortIV®)Procedure or surgery
Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
standard cureProcedure or surgery
The standard cure consists of:
- Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.
- Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus).
| Study group | Role | What they receive |
|---|---|---|
| Control | Active comparator | After cannulation of a midline catheter or peripherally inserted central venous catheter with modified micro-Seldinger technique, the control group underwent standard care. Receives: Procedure: standard cure |
| Intervention | Experimental | After cannulation of a midline catheter or peripherally inserted central venous catheter with a modified micro-Seldinger technique, the intervention group underwent the standard treatment plus application of cyanoacrylate tissue adhesive (SecurePortIV®) at the puncture site. Receives: Procedure: cyanoacrylate adhesive (SecurePortIV®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Percentage of participants with adverse events after being treated with cyanoacrylate tissue adhesive at the puncture site after insertion of cannulated middle and central venous catheters with the modified micro-Seldinger technique.
Measured: 7 days
Secondary outcomes (4)
Number of participants with post-treatment hemorrhage assessed by observation (yes/no).
Percentage of participants with pericatheter bleeding after puncture of a midline or central venous catheter with the modified micro-Seldinger technique. Four cures will be performed: post puncture, at 24 hours, 72 hours and 7 days, where the puncture site will be visualized for signs of bleeding and it will be noted whether there is bleeding or not.
Measured: 7 days
Number of participants with post-treatment catheter displacement assessed by observation (yes/no).
Percentage of participants with catheter displacement after puncture of a midline or central venous catheter with the modified micro-Seldinger technique. Four cures will be performed: post puncture, at 24 hours, 72 hours and 7 days, where the puncture site will be visualized to check if the catheter is still in the same point or if it has been displaced.
Measured: 7 days
Number of participants with post-treatment phlebitis assessed with the Maddox visual phlebitis rating scale.
Percentage of participants with phlebitis after puncture of a midline or central venous catheter with the modified micro-Seldinger technique. Four cures will be performed: post puncture, at 24 hours, 72 hours and 7 days, where the puncture site will be visualized to check for signs of phlebitis, according to the Maddox scale.
Measured: 7 days
Number of participants with post-treatment pain in extremity assessed with the EVA scale.
Percentage of participants with pain in extremity after puncture of a midline or central venous catheter with the modified micro-Seldinger technique. Four cures will be performed: post puncture, at 24 hours, 72 hours and 7 days, where the patient will be asked what pain he/she feels in the extremity related to the catheter.
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2022
- Study start16 Sep 2020
- Primary completion30 Sep 2021
- Study completion30 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (28)Papers the sponsor has linked to this study.
- Other trials for Vascular Access DeviceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Classical parallel model with an intervention group, to which cyanoacrylate tissue adhesive was applied, and a control group.
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 216 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Arnau de Vilanova
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ferran Padilla Nula, Hospital Arnau de Vilanova
- Investigators
- Ferran Padilla-Nula, Principal investigator, Arnau de Vilanova hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05299060
- Sponsor's protocol ID
- 01-20
- Acronym
- CIANO-ETI
- Status last verified
- Sep 2022
- First submitted
- 26 Feb 2022
- Last updated
- 8 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Contact the principal investigator by mail: FPADILLA@gencat.cat
Publications
Alexandrou E, Ray-Barruel G, Carr PJ, Frost S, Inwood S, Higgins N, Lin F, Alberto L, Mermel L, Rickard CM. International prevalence of the use of peripheral intravenous catheters. J Hosp Med. 2015 Aug;10(8):530-3. doi: 10.1002/jhm.2389. Epub 2015 Jun 3.
PubMed 26041384Fabiani A, Eletto V, Dreas L, Beltrame D, Sanson G. Midline or long peripheral catheters in difficult venous access conditions? A comparative study in patients with acute cardiovascular diseases. Am J Infect Control. 2020 Oct;48(10):1158-1165. doi: 10.1016/j.ajic.2019.12.025. Epub 2020 Jan 21.
PubMed 31973988Kang J, Chen W, Sun W, Ge R, Li H, Ma E, Su Q, Cheng F, Hong J, Zhang Y, Lei C, Wang X, Jin A, Liu W. Peripherally inserted central catheter-related complications in cancer patients: a prospective study of over 50,000 catheter days. J Vasc Access. 2017 Mar 21;18(2):153-157. doi: 10.5301/jva.5000670. Epub 2017 Feb 8.
PubMed 28218366Bodenham A. Vascular acces. Rev Med Clin Condes [Internet]. 2017;28(5):701-12. Available from: http://dx.doi.org/10.1016/j.rmclc.2017.07.011
Corley A, Marsh N, Ullman AJ, Rickard CM. Tissue adhesive for vascular access devices: who, what, where and when? Br J Nurs. 2017 Oct 26;26(19):S4-S17. doi: 10.12968/bjon.2017.26.19.S4.
PubMed 29068728Lacostena-Perez ME, Buesa-Escar AM, Gil-Alos AM. Complications related to the insertion and maintenance of peripheral venous access central venous catheter. Enferm Intensiva (Engl Ed). 2019 Jul-Sep;30(3):116-126. doi: 10.1016/j.enfi.2018.05.002. Epub 2018 Sep 3. English, Spanish.
PubMed 30190250Fujioka G, Newcomb P, Hunchusky C, Myers H, Behan D. Pain Perception of a Structured Vascular Access Team Approach to Short Peripheral Catheter (SPC) Placement Compared to SPC Placement by Bedside Nurses. J Infus Nurs. 2020 Jan/Feb;43(1):33-38. doi: 10.1097/NAN.0000000000000352.
PubMed 31876772Braga LM, Parreira PM, Oliveira ASS, Monico LDSM, Arreguy-Sena C, Henriques MA. Phlebitis and infiltration: vascular trauma associated with the peripheral venous catheter. Rev Lat Am Enfermagem. 2018;26:e3002. doi: 10.1590/1518-8345.2377.3002. Epub 2018 May 17.
PubMed 29791668Ellis ML, Okano S, McCann A, McDowall A, Van Kuilenburg R, McCarthy AL, Joubert W, Harper J, Jones M, Mollee P. Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Intern Med J. 2020 Dec;50(12):1475-1482. doi: 10.1111/imj.14780.
PubMed 32043739Moureau N. Impact and Safety Associated with Accidental Dislodgement of Vascular Access Devices: A Survey of Professions, Settings, and Devices. JAVA - J Assoc Vasc Access. 2018 Dec 1;23(4):203-15.
Nicholson J, Hill J. Cyanoacrylate tissue adhesive: a new tool for the vascular access toolbox. Br J Nurs. 2019 Oct 24;28(19):S22-S28. doi: 10.12968/bjon.2019.28.19.S22.
PubMed 31647725Chaves F, Garnacho-Montero J, Del Pozo JL, Bouza E, Capdevila JA, de Cueto M, Dominguez MA, Esteban J, Fernandez-Hidalgo N, Fernandez Sampedro M, Fortun J, Guembe M, Lorente L, Pano JR, Ramirez P, Salavert M, Sanchez M, Valles J. Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC). Med Intensiva (Engl Ed). 2018 Jan-Feb;42(1):5-36. doi: 10.1016/j.medin.2017.09.012. English, Spanish.
PubMed 29406956Mihala G, Ray-Barruel G, Chopra V, Webster J, Wallis M, Marsh N, McGrail M, Rickard CM. Phlebitis Signs and Symptoms With Peripheral Intravenous Catheters: Incidence and Correlation Study. J Infus Nurs. 2018 Jul/Aug;41(4):260-263. doi: 10.1097/NAN.0000000000000288.
PubMed 29958263O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011 May;52(9):e162-93. doi: 10.1093/cid/cir257. Epub 2011 Apr 1. No abstract available.
PubMed 21460264Song IK, Kim EH, Lee JH, Jang YE, Kim HS, Kim JT. Seldinger vs modified Seldinger techniques for ultrasound-guided central venous catheterisation in neonates: a randomised controlled trial. Br J Anaesth. 2018 Dec;121(6):1332-1337. doi: 10.1016/j.bja.2018.08.008. Epub 2018 Sep 7.
PubMed 30442261
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Cyanoacrylate Glue in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients: Randomised Clinical Trial (CIANO-ETI)
- ClinicalTrials.gov ID
- NCT05299060
- Acronym / sponsor ID
- CIANO-ETI / 01-20
- Conditions
- Vascular Access Device, Catheterization, Peripheral, Nursing Care, Randomized Controlled Trial
- Keywords
- Cyanoacrylates, Cyanoacrylate, Tissue adhesive
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 216 participants (actual)
- Lead sponsor
- Hospital Arnau de VilanovaUniversity, hospital or other
- Study start
- 16 Sep 2020 (actual)
- Primary completion
- 30 Sep 2021 (actual)
- Study completion
- 30 Sep 2021 (actual)
- First posted
- 28 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Venous access is increasingly necessary and essential in healthcare institutions, where more than 75% of hospitalised patients have some type of vascular access device cannulated. Due to their pathophysiological characteristics and pharmacological needs, some patients require special catheters, such as midline or peripherally inserted central catheters. In an attempt to reduce the main complications related to these, the safety of cyanoacrylate tissue adhesive has recently been demonstrated in the post-insertion treatment of vascular access devices.
Objective: To evaluate the efficacy of the use of cyanoacrylate tissue adhesive as fixation in the post-insertion of cannulated middle and central venous catheters with modified micro-Seldinger technique in acute hospitalized patients.
Methods: Randomised clinical trial with two groups(1:1): control and intervention. The control group received a cure with sutureless device plus transparent membrane and the intervention group received the same cure plus the cyanoacrylate glue. The study was approved by the Drug Research Ethics Committee of the Lleida health region. health region.
KEYWORDS: Cyanoacrylates; Vascular Access Device; Catheterization, Peripheral; Nursing Care; Randomized Controlled Trial.
Detailed description
A randomized clinical study with two arms (control group and intervention group) was performed.
Patients were selected according to whether they met the inclusion/exclusion criteria and all patients who met the criteria were offered to participate on a voluntary basis. These were collected by the intravenous therapy team (ETI) of the Arnau de Vilanova University Hospital (HUAV) in Lleida, from September 16, 2020 until the completion of the collection of the total number of patients required for the study (n=216).
Patients required insertion of a midline venous catheter (BD-18580 PowerMidline™ 4F) or a peripherally inserted central catheter (BD-20178 PowerPICC™ 4,5 or 6 F), according to the ETI-HUAV algorithm. All insertions were performed with the aid of ultrasound as a guiding technique. In addition, all patients underwent dermatotomy during the technique and the application of a post-insertion hemostasis protocol for at least 2 minutes or until the insertion site stopped bleeding, in order to unify the researchers' criteria.
After insertion of the vascular access device, the control group underwent the standard dressing: transparent polyurethane dressing with reinforced edge (3M®-1655 Tegaderm™ IV) and Sutureless Fixation Device (BD-19940 StatLock™ PICC Plus); and the intervention group, the standard dressing plus application of cyanoacrylate tissue adhesive (SP-015V SecurePortIV™ from Adhezion Biomedical, Llc.).
Afterwards, 3 scheduled cures were performed, at 24 hours, 72 hours and 7 days post-insertion, looking for the main complications: bleeding and/or pericatheter exudate, catheter displacement, signs of phlebitis and catheter-related pain.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
- Model description
- Classical parallel model with an intervention group, to which cyanoacrylate tissue adhesive was applied, and a control group.
| Arm | Type | Receives |
|---|---|---|
| Control | Active comparator | Procedure: standard cureAfter cannulation of a midline catheter or peripherally inserted central venous catheter with modified micro-Seldinger technique, the control group underwent standard care. |
| Intervention | Experimental | Procedure: cyanoacrylate adhesive (SecurePortIV®)After cannulation of a midline catheter or peripherally inserted central venous catheter with a modified micro-Seldinger technique, the intervention group underwent the standard treatment plus application of cyanoacrylate tissue adhesive (SecurePortIV®) at the puncture site. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- over 18 years of age
- requiring cannulation of a midline catheter (BD-18580 PowerMidline™ 4F) or a PICC (BD-20178 PowerPICC™ 4.5 or 6 F)
- who accepted and signed the informed consent voluntarily
- with an inpatient unit admission of minimum 7 days
Key exclusion criteria (1 listed)
- patients with skin conditions contraindicating the application of a skin glue or known allergy to cyanoacrylate, as recorded in the clinical history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cyanoacrylate adhesive (SecurePortIV®)Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care. | Procedure or surgery | Intervention |
| standard cureThe standard cure consists of: * Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops. * Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus). | Procedure or surgery | Control |
Primary outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Time frame: 7 days
Percentage of participants with adverse events after being treated with cyanoacrylate tissue adhesive at the puncture site after insertion of cannulated middle and central venous catheters with the modified micro-Seldinger technique.
4 secondary outcomes
Number of participants with post-treatment hemorrhage assessed by observation (yes/no).
Time frame: 7 days
Number of participants with post-treatment catheter displacement assessed by observation (yes/no).
Time frame: 7 days
Number of participants with post-treatment phlebitis assessed with the Maddox visual phlebitis rating scale.
Time frame: 7 days
Number of participants with post-treatment pain in extremity assessed with the EVA scale.
Time frame: 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2022.
- Background: PubMed 26041384Alexandrou E, Ray-Barruel G, Carr PJ, Frost S, Inwood S, Higgins N, Lin F, Alberto L, Mermel L, Rickard CM. International prevalence of the use of peripheral intravenous catheters. J Hosp Med. 2015 Aug;10(8):530-3. doi: 10.1002/jhm.2389. Epub 2015 Jun 3.
- Background: PubMed 31973988Fabiani A, Eletto V, Dreas L, Beltrame D, Sanson G. Midline or long peripheral catheters in difficult venous access conditions? A comparative study in patients with acute cardiovascular diseases. Am J Infect Control. 2020 Oct;48(10):1158-1165. doi: 10.1016/j.ajic.2019.12.025. Epub 2020 Jan 21.
- Background: PubMed 28218366Kang J, Chen W, Sun W, Ge R, Li H, Ma E, Su Q, Cheng F, Hong J, Zhang Y, Lei C, Wang X, Jin A, Liu W. Peripherally inserted central catheter-related complications in cancer patients: a prospective study of over 50,000 catheter days. J Vasc Access. 2017 Mar 21;18(2):153-157. doi: 10.5301/jva.5000670. Epub 2017 Feb 8.
- BackgroundBodenham A. Vascular acces. Rev Med Clin Condes [Internet]. 2017;28(5):701-12. Available from: http://dx.doi.org/10.1016/j.rmclc.2017.07.011
- Background: PubMed 29068728Corley A, Marsh N, Ullman AJ, Rickard CM. Tissue adhesive for vascular access devices: who, what, where and when? Br J Nurs. 2017 Oct 26;26(19):S4-S17. doi: 10.12968/bjon.2017.26.19.S4.
- Background: PubMed 30190250Lacostena-Perez ME, Buesa-Escar AM, Gil-Alos AM. Complications related to the insertion and maintenance of peripheral venous access central venous catheter. Enferm Intensiva (Engl Ed). 2019 Jul-Sep;30(3):116-126. doi: 10.1016/j.enfi.2018.05.002. Epub 2018 Sep 3. English, Spanish.
- Background: PubMed 31876772Fujioka G, Newcomb P, Hunchusky C, Myers H, Behan D. Pain Perception of a Structured Vascular Access Team Approach to Short Peripheral Catheter (SPC) Placement Compared to SPC Placement by Bedside Nurses. J Infus Nurs. 2020 Jan/Feb;43(1):33-38. doi: 10.1097/NAN.0000000000000352.
- Background: PubMed 29791668Braga LM, Parreira PM, Oliveira ASS, Monico LDSM, Arreguy-Sena C, Henriques MA. Phlebitis and infiltration: vascular trauma associated with the peripheral venous catheter. Rev Lat Am Enfermagem. 2018;26:e3002. doi: 10.1590/1518-8345.2377.3002. Epub 2018 May 17.
- Background: PubMed 32043739Ellis ML, Okano S, McCann A, McDowall A, Van Kuilenburg R, McCarthy AL, Joubert W, Harper J, Jones M, Mollee P. Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Intern Med J. 2020 Dec;50(12):1475-1482. doi: 10.1111/imj.14780.
- BackgroundMoureau N. Impact and Safety Associated with Accidental Dislodgement of Vascular Access Devices: A Survey of Professions, Settings, and Devices. JAVA - J Assoc Vasc Access. 2018 Dec 1;23(4):203-15.
- Background: PubMed 31647725Nicholson J, Hill J. Cyanoacrylate tissue adhesive: a new tool for the vascular access toolbox. Br J Nurs. 2019 Oct 24;28(19):S22-S28. doi: 10.12968/bjon.2019.28.19.S22.
- Background: PubMed 29406956Chaves F, Garnacho-Montero J, Del Pozo JL, Bouza E, Capdevila JA, de Cueto M, Dominguez MA, Esteban J, Fernandez-Hidalgo N, Fernandez Sampedro M, Fortun J, Guembe M, Lorente L, Pano JR, Ramirez P, Salavert M, Sanchez M, Valles J. Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC). Med Intensiva (Engl Ed). 2018 Jan-Feb;42(1):5-36. doi: 10.1016/j.medin.2017.09.012. English, Spanish.
- Individual participant dataSharing planned: Yes. Contact the principal investigator by mail: FPADILLA@gencat.cat
Related trials for Vascular Access Device
Active, not recruiting
Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Enrolling by invitation
TruVascular Access - Ultrasound-Guided Vascular Access Study
Peripheral Venous Catheterization, Difficult Intravenous Access
Not yet recruiting
Impact of a Long Peripheral Venous Catheter Protocol in Pediatric and Neonatal Care
Vascular Access Devices, Vascular Access
RecruitingObservational study
Abbott Vascular Medical Device Registry
Acute Myocardial Infarction, Restenoses, Coronary
Not yet recruiting
Safety and Effectiveness Clinical Study of Novelrad Vascular Closure System (NVCS)
Vascular Closure Device, Femoral Arteriotomy Closure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ferran Padilla-Nula principal investigator
Arnau de Vilanova hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing cyanoacrylate adhesive (SecurePortIV®) and standard cure in people with Vascular Access Device and Catheterization, Peripheral, run by Hospital Arnau de Vilanova at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. (time frame: 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05299060, which also lists 28 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2022.